Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label, 52 Week, Dose-escalation Study of SP 420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Next Previous
Search
Trial Profile

Multicenter, Open-label, 52 Week, Dose-escalation Study of SP 420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SP 420 (Primary)
  • Indications Iron overload
  • Focus Adverse reactions
  • Sponsors Abfero Pharmaceuticals

    • Most Recent Events

    • 06 Oct 2020 According to Clinicaltrials.gov the study was stopped because the protocol was suspended prior to patient enrollment.
    • 30 Sep 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 24 Feb 2020 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top